MetaVia (MTVA) AI Stock Analysis

• Market Cap: $5.11M
• Dividend Yield: N/A
• Average Volume (3M): 3.42M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.39
• Revenue Growth: N/A
• EPS Growth: 71.57%
• Country: US
• Employees: 9
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.54
• Shares Outstanding: 3,315,164
• 10 Day Avg. Volume: 118,677
• 30 Day Avg. Volume: 3,419,960
• PEG Ratio: -0.01
• Price to Book (P/B): 1.99
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.64
• Enterprise Value/Market Cap: -2.11
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 599.21
• Enterprise Value/Ebitda: 0.64
• 1Y Price Target: $47.50
• Price Target Upside: 2964.52% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $2.50 ▲(61.29% Upside)
• Action: Reiterated Date: 01/17/26
• Date: Action: Reiterated 01/17/26

The score is held down primarily by persistent pre-revenue losses and worsening cash burn with a shrinking equity base, implying continued funding risk. Technicals also point to a clear downtrend despite oversold readings. Offsetting these are multiple positive clinical readouts and a recent financing that strengthens near-term liquidity and reduces listing-related risk.

Positive Factors

Positive Phase 1 DA-1726 obesity data

Robust Phase 1 weight-loss and metabolic signals materially strengthen MetaVia’s lead obesity program and clinical differentiation as a GLP-1/glucagon dual agonist. Persistently strong safety and hepatic effects improve the program's commercial potential and de-risk the development pathway over the next 2–6 months.

Positive Phase 2a vanoglipel (DA-1241) MASH results

Positive Phase 2a efficacy across glycemic and liver endpoints expands MetaVia’s clinical value proposition beyond obesity into MASH, increasing strategic optionality. A successful late-stage profile for vanoglipel can enable multiple commercial pathways (monotherapy or combos), supporting durable long-term growth if confirmatory trials succeed.

Near-term liquidity from public offering

The $7.7M net proceeds extend runway and fund ongoing DA-1726 development, reducing immediate delisting and working-capital pressure. While not a long-term solution, this financing materially lowers near-term liquidity risk and permits continued execution on clinical milestones over the next several months.

Negative Factors

Pre-revenue with widening operating losses

MetaVia remains pre-revenue and reported substantially wider operating losses in 2024. Without a commercial product, recurring losses must be funded externally; this structural lack of revenue means continued dependence on capital markets and heightens execution risk if trial timelines slip or readouts disappoint.

Accelerating cash burn and negative free cash flow

Steep, cash-based losses create a persistent financing need. Accelerating operating cash outflows substantially increase the probability of future dilutive raises, constrain discretionary investment in trials, and shorten runway absent material trial-driven value inflection or further financing.

Shrinking equity and dilution risk from financings

A materially smaller equity base reduces the firm’s capital cushion and increases sensitivity to financing cycles. The company’s recent issuance of warrants and offerings signals reliance on dilutive instruments, meaning future capital raises may materially dilute shareholders and affect long-term capital structure stability.

MetaVia Business Overview & Revenue Model

Company Description

MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

MetaVia makes money through a diversified revenue model that includes subscription fees for access to its virtual reality platforms and premium content. Additionally, the company generates income through partnerships with other digital service providers and developers who create content for its platforms, often sharing in the revenue generated from these collaborations. Furthermore, MetaVia earns from in-app purchases and virtual goods sales within its ecosystem. Advertising is another key revenue stream, as brands pay for exposure within the virtual environments and experiences offered by MetaVia.

MetaVia Financial Statement Overview

Summary

Very weak operating fundamentals: no revenue across 2019–2024, widening losses in 2024, and accelerating cash burn (operating cash flow about -$24.7M in 2024 vs. -$10.8M in 2023). Positives include very low leverage (debt-to-equity near zero), but equity has shrunk materially, increasing reliance on external financing.

Income Statement

MetaVia reports no revenue across 2019–2024, with persistent and sizable operating losses. Losses widened in 2024 (EBIT of about -$28.8M vs. -$15.9M in 2023), and net income also deteriorated (about -$27.6M vs. -$12.5M). A modest positive is that losses have not been consistently worsening every year (e.g., 2021–2023 were less negative than 2020), but the lack of a revenue base and recurring losses are the dominant weakness.

Balance Sheet

The balance sheet shows very low leverage (debt-to-equity remains near zero to ~0.02), which reduces financial risk and provides flexibility. However, equity has declined materially over time (from ~$21.8M in 2022 to ~$7.9M in 2024), reflecting ongoing losses and a shrinking capital cushion; returns on equity are deeply negative in 2024. Assets also declined versus 2022, underscoring balance-sheet contraction.

Cash Flow

Cash burn is substantial and worsening: operating cash flow fell from about -$10.8M in 2023 to about -$24.7M in 2024, with free cash flow similarly negative (~-$24.7M in 2024). Free cash flow tracks net loss closely (roughly one-to-one), which suggests losses are largely cash-based rather than accounting-only. While the year-to-year free cash flow growth rate is positive in 2024 (i.e., less negative in some prior periods and more negative in others), the overall trajectory highlights ongoing funding needs and elevated liquidity risk absent new capital.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Mar 2022	Mar 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-18.00K	-24.00K	-7.00K	-28.00K	-72.00K	-67.00K
EBITDA	-16.92M	-28.79M	-15.88M	-11.76M	-15.24M	-29.67M
Net Income	-16.22M	-27.59M	-12.47M	-13.97M	-15.28M	-29.68M
Balance Sheet
Total Assets	14.77M	16.26M	22.78M	33.53M	16.80M	10.97M
Cash, Cash Equivalents and Short-Term Investments	14.28M	16.02M	22.43M	33.36M	16.39M	10.09M
Total Debt	79.00K	136.00K	203.00K	0.00	71.00K	94.00K
Total Liabilities	8.43M	8.33M	6.10M	11.78M	2.20M	3.77M
Stockholders Equity	6.33M	7.93M	16.68M	21.75M	14.60M	7.20M
Cash Flow
Free Cash Flow	-16.27M	-24.72M	-10.85M	-11.71M	-15.14M	-10.77M
Operating Cash Flow	-16.27M	-24.71M	-10.80M	-11.71M	-15.13M	-10.76M
Investing Cash Flow	-2.00K	-8.00K	-50.00K	8.00K	-586.00K	69.00K
Financing Cash Flow	8.88M	18.30M	-80.00K	28.68M	22.03M	6.86M

MetaVia Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.55
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MTVA, the sentiment is Negative. The current price of 1.55 is below the 20-day moving average (MA) of 1.98, below the 50-day MA of 5.39, and below the 200-day MA of 7.76, indicating a bearish trend. The MACD of -1.04 indicates Negative momentum. The RSI at 21.96 is Positive, neither overbought nor oversold. The STOCH value of 22.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MTVA.

MetaVia Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PMN	52 Neutral	$35.06M	-0.87	-355.80%	―	―	-273.84%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RLYB	48 Neutral	$23.50M	-1.86	-21.17%	―	12.71%	79.93%
MTVA	46 Neutral	$5.11M	-0.10	-168.18%	―	―	71.57%
CTXR	45 Neutral	$16.05M	-0.24	-54.40%	―	―	18.73%

MetaVia Corporate Events

MetaVia Updates 2025 Executive Discretionary Bonus Disclosure

On January 5, 2026, MetaVia Inc. filed a registration statement that referenced yet-to-be-determined discretionary cash bonuses for its principal executive officer and up to two other highly compensated executives for the fiscal year ended December 31, 2025. On January 23, 2026, the company’s compensation committee approved those bonuses, and MetaVia subsequently updated its executive compensation disclosure to include the 2025 discretionary cash bonus amounts and total compensation figures for its named executive officers, providing investors with a more complete picture of management pay for that fiscal year.

The most recent analyst rating on (MTVA) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on MetaVia stock, see the MTVA Stock Forecast page.

MetaVia Completes Public Offering to Advance Obesity Drug

On January 15–16, 2026, MetaVia Inc. completed an underwritten public offering of Class A and Class B units, consisting of common stock, pre-funded warrants and Series C and Series D common warrants, raising approximately $7.7 million in net proceeds after discounts and expenses from gross proceeds of about $8.1 million. The transaction, led by Ladenburg Thalmann & Co. Inc., included full exercise of the underwriter’s over-allotment option and established a package of fixed-price, immediately exercisable warrants, some of which are subject to beneficial ownership limits and potential future callability tied to positive Phase 1b Part III data for DA-1726; MetaVia plans to deploy the capital for working capital and general corporate purposes, notably to advance clinical development of DA-1726 for obesity, reinforcing its funding base and strategic focus in the competitive cardiometabolic drug development arena.

The most recent analyst rating on (MTVA) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on MetaVia stock, see the MTVA Stock Forecast page.

MetaVia Reports Encouraging Phase 1 DA-1726 Obesity Data

On January 5, 2026, MetaVia reported positive, statistically significant data from the extended eight-week, non-titrated 48 mg multiple ascending dose cohort of its Phase 1 clinical trial of DA-1726 in obese but otherwise healthy adults, highlighting robust early weight loss, strong metabolic improvements and direct hepatic effects. Patients receiving DA-1726 achieved an average 9.1% (21.2 lb) weight loss, a 9.8 cm reduction in waist circumference, a 12.3 mg/dL drop in fasting glucose and a 23.7% reduction in liver stiffness by Day 54, with no treatment-related discontinuations and only mild to moderate gastrointestinal events, underscoring a favorable safety and tolerability profile and reinforcing DA-1726’s potential to emerge as a differentiated, best-in-class GLP-1/glucagon dual agonist in the increasingly competitive obesity and metabolic disease market.

The most recent analyst rating on (MTVA) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on MetaVia stock, see the MTVA Stock Forecast page.

MetaVia Regains Nasdaq Compliance After Bid Price Recovery

On May 29, 2025, MetaVia Inc. was notified by Nasdaq that it was not in compliance with the exchange’s $1.00 minimum bid price requirement after its shares traded below that threshold for 30 consecutive sessions, prompting the company on November 7, 2025 to seek, and on November 26, 2025 to receive, a 180‑day extension to May 26, 2026 to cure the deficiency. The company subsequently regained compliance when its stock closed at or above $1.00 for 10 straight business days from December 5 to December 18, 2025, leading Nasdaq on December 19, 2025 to confirm that MetaVia once again met the minimum bid price standard and that the listing matter was closed, removing a near‑term risk to its continued trading on the exchange.

The most recent analyst rating on (MTVA) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on MetaVia stock, see the MTVA Stock Forecast page.

MetaVia Announces Reverse Stock Split to Meet Nasdaq Rules

On December 2, 2025, MetaVia Inc. announced a 1-for-11 reverse stock split of its common stock, effective December 4, 2025, to comply with Nasdaq’s listing requirements. This decision, approved by the stockholders on June 30, 2025, reduces the number of outstanding shares from approximately 25.4 million to 2.3 million, while maintaining the authorized shares at 100 million. The reverse split will adjust the conversion and exercise prices of stock options and warrants proportionately, with fractional shares being rounded down and compensated in cash. The common stock will continue trading under the symbol ‘MTVA’ with a new CUSIP number.

The most recent analyst rating on (MTVA) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on MetaVia stock, see the MTVA Stock Forecast page.

MetaVia Seeks Extension to Regain Nasdaq Compliance

On May 29, 2025, MetaVia Inc. received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement, as its stock price had been below $1.00 for 30 consecutive trading days. The company requested a 180-day extension on November 7, 2025, to regain compliance, planning to potentially implement a reverse stock split to meet the requirement.

The most recent analyst rating on (MTVA) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on MetaVia stock, see the MTVA Stock Forecast page.

MetaVia Announces Positive Phase 2a Trial Results

On November 7, 2025, MetaVia Inc. announced positive results from its Phase 2a clinical trial of vanoglipel (DA-1241), a GPR119 agonist, as a potential treatment for MASH. The trial demonstrated vanoglipel’s ability to improve glucose control, liver health, and plasma lipidomic profiles after 16 weeks of treatment, highlighting its potential to address both hepatic and metabolic components of MASH. The data, presented at the AASLD The Liver Meeting® 2025, showed significant reductions in HbA1c, liver inflammation, and fibrosis, reinforcing vanoglipel’s potential as a monotherapy and combination therapy for MASH and related metabolic disorders.

The most recent analyst rating on (MTVA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on MetaVia stock, see the MTVA Stock Forecast page.

MetaVia Releases Updated Corporate Presentation on Trials

On November 6, 2025, MetaVia Inc. released an updated corporate presentation detailing its ongoing clinical trials and future milestones. The company is making significant progress with its DA-1726 and Vanoglipel (DA-1241) candidates, showing promising results in weight loss and glucose control, which could enhance its market position. MetaVia is also planning further clinical trials and regulatory submissions, potentially increasing shareholder value and impacting the treatment landscape for obesity and MASH.

The most recent analyst rating on (MTVA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on MetaVia stock, see the MTVA Stock Forecast page.